Zhejiang Jolly Pharmaceutical Co., Ltd. (300181) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Negative results in Mar 25

INTEREST(9M) At CNY 7.97 MM has Grown at 38.41%
OPERATING CASH FLOW(Y) Lowest at CNY 202.54 MM
DEBT-EQUITY RATIO (HY) Highest at -4.77 %

With ROE of 19.59%, it has a attractive valuation with a 2.70 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 8,205 Million (Large Cap)

P/E

14.00

Industry P/E

Dividend Yield

5.13%

Debt Equity

-0.00

Return on Equity

19.59%

Price to Book

2.70

Revenue and Profits:

Net Sales:

765 Million

(Quarterly Results - Jun 2025)

Net Profit:

196 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.79%

6 Months

-4.11%

1 Year

-0.76%

2 Years

61.79%

3 Years

43.51%

4 Years

107.81%

5 Years

153.65%

Zhejiang Jolly Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

23.78%

EBIT Growth (5y)

93.87%

EBIT to Interest (avg)

33.25

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.05

Sales to Capital Employed (avg)

0.71

Tax Ratio

13.81%

Dividend Payout Ratio

82.35%

Pledged Shares

Institutional Holding

ROCE (avg)

14.41%

ROE (avg)

12.89%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.70

EV to EBIT

13.23

EV to EBITDA

11.71

EV to Capital Employed

2.71

EV to Sales

3.01

PEG Ratio

0.63

Dividend Yield

5.13%

ROCE (Latest)

20.48%

ROE (Latest)

19.59%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -6.45% vs 55.77% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 6.76% vs 107.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "765.30",
          "val2": "818.10",
          "chgp": "-6.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "234.20",
          "val2": "213.90",
          "chgp": "9.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.90",
          "val2": "2.80",
          "chgp": "39.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "195.80",
          "val2": "183.40",
          "chgp": "6.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "279.40%",
          "val2": "236.50%",
          "chgp": "4.29%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.92% vs 7.44% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.04% vs 36.88% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,548.80",
          "val2": "1,917.50",
          "chgp": "32.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "665.60",
          "val2": "490.30",
          "chgp": "35.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.40",
          "val2": "7.70",
          "chgp": "22.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "516.00",
          "val2": "390.80",
          "chgp": "32.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "231.60%",
          "val2": "220.00%",
          "chgp": "1.16%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

765.30

818.10

-6.45%

Operating Profit (PBDIT) excl Other Income

234.20

213.90

9.49%

Interest

3.90

2.80

39.29%

Exceptional Items

0.00

Consolidate Net Profit

195.80

183.40

6.76%

Operating Profit Margin (Excl OI)

279.40%

236.50%

4.29%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -6.45% vs 55.77% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 6.76% vs 107.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2,548.80

1,917.50

32.92%

Operating Profit (PBDIT) excl Other Income

665.60

490.30

35.75%

Interest

9.40

7.70

22.08%

Exceptional Items

0.00

Consolidate Net Profit

516.00

390.80

32.04%

Operating Profit Margin (Excl OI)

231.60%

220.00%

1.16%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 32.92% vs 7.44% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 32.04% vs 36.88% in Dec 2023

All Annual Results

Company CV

About Zhejiang Jolly Pharmaceutical Co., Ltd.

Zhejiang Jolly Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available